Clinical Trials Logo

Hyperplasia clinical trials

View clinical trials related to Hyperplasia.

Filter by:

NCT ID: NCT06365905 Recruiting - Clinical trials for Endometrial Carcinoma

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

Start date: June 1, 2024
Phase:
Study type: Observational

This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions.

NCT ID: NCT06342440 Recruiting - Colorectal Cancer Clinical Trials

Early Detection of Advanced Adenomas and Colorectal Cancer

AACRC
Start date: March 15, 2020
Phase:
Study type: Observational

This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.

NCT ID: NCT06319469 Completed - Clinical trials for Prostatic Hyperplasia

The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

Acute urine retention, AUR, is often considered the most serious consequence of aging men with progressive benign prostatic hyperplasia (BPH). AUR is defined as the sudden and painful inability to void freely. This study aims to evaluate whether pyridostigmine bromide added to silodosin is beneficial in treating acute urine retention caused by BPH.

NCT ID: NCT06315062 Completed - Clinical trials for Benign Hyperplasia of Prostate

Efficacy of Rezum® in Reducing Prostate Volume

Start date: January 1, 2020
Phase:
Study type: Observational

This study aimed to assess the efficacy of Rezum® water vapor therapy in reducing prostate volume in patients aged 40 years or older with Benign Prostate Hyperplasia (BPH) at UNIBE Hospital in Costa Rica. A retrospective analysis will be conducted on 289 patient records, focusing on prostate volume, International Prostate Symptom Score (IPSS), and urinary flow rate. Statistical analyses included two-sample mean comparisons, effect size estimation, and linear regression.

NCT ID: NCT06312722 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study

PEAK
Start date: February 7, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to verify the continued safety and effectiveness for the Optilume BPH Catheter System.

NCT ID: NCT06310538 Not yet recruiting - Breast Hyperplasia Clinical Trials

Clinical Study on the Treatment of Breast Hyperplasia With Kou Sha Therapy Based on Real World

Start date: March 2024
Phase: N/A
Study type: Interventional

In this study, epidemiological prospective real-world cohort study design was adopted. The Third Affiliated Hospital of Beijing University of Chinese Medicine and the First Hospital of Handan City, Hebei Province were selected. From the same time appointed before the study, all breast hyperplasia participants who met the admission criteria choosing Kou Sha therapy or routine treatment of western medicine were selected in the sample hospitals.The first 30 participants were included in the planned Kou Sha therapy group while the first 30 participants were included in the control group.Taking the change of the total score of breast pain (McGill Pain Questionnaire Short Form score+breast pain score) as the main curative effect index, and taking McGill pain questionnaire score, breast color ultrasound score, palpation lump score, quality of life, anxiety and depression symptoms, sleep and so on as the secondary curative effect indexes to observe the clinical effect of the method of Kou Sha therapy on breast hyperplasia. The research period is from March 2024 to May 2024.

NCT ID: NCT06294366 Recruiting - Clinical trials for Prostatic Hyperplasia

Bipolar Transurethral Enucleation Versus Resection in the Treatment of Benign Prostatic Hyperplasia: a Comparative Study

Start date: June 12, 2022
Phase: N/A
Study type: Interventional

Benign prostatic hyperplasia (BPH) is a common chronic progressive disease resulting in the enlargement of the prostate gland and bladder outlet obstruction in aging men . Because of the increasing aged population and advancements in diagnostic tools, the incidence and importance of BPH have increased . BPH can be treated either with watchful waiting, drug therapy, or surgery being the most effective treatment option for BPH . Transurethral resection of the prostate (TURP) has been recognized as the standard treatment for BPH with morbidity rate varies from 18% and 26% Until now, only open prostatectomy and transurethral Holmium laser enucleation of the prostate (HoLEP) have shown an equal efficacy and durability compared to TURP

NCT ID: NCT06282731 Completed - Clinical trials for Benign Prostatic Hyperplasia

The Changes of Urine Growth Factors Level

Start date: May 31, 2013
Phase: Early Phase 1
Study type: Interventional

The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia after medical treatment.

NCT ID: NCT06281392 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Artificial Intelligence and Dysplasia Detection in Inflammatory Bowel Disease (EIIDISIA Study)

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

Randomized clinical study analyzing the efficacy of colonoscopy assisted by the Computer Aided Detection (CADe) system compared to virtual chromoendoscopy with Narrow Band Imaging (NBI) in the detection of colon dysplasia in patients with long-standing inflammatory bowel disease (IBD).

NCT ID: NCT06275256 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

Outcomes of MIST for BPH: A Single-Institution Prospective Study

Start date: March 2024
Phase: Phase 3
Study type: Interventional

The investigators wish to perform a prospective study at the Men's Health Clinic in Winnipeg, Manitoba to accomplish two goals: 1) Prospectively describe 1 year outcomes for MIST therapies performed at the clinic 2) perform a head to head comparison of Rezum water vapor therapy vs the iTind device in respect to symptom score improvement, uroflow parameters and side effect profile.